Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $6.86 Million - $11.8 Million
-47,900 Reduced 14.48%
283,000 $68.8 Million
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $39.1 Million - $52.9 Million
266,900 Added 417.03%
330,900 $49.5 Million
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $7.51 Million - $9.75 Million
-49,600 Reduced 43.66%
64,000 $12.3 Million
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $16.4 Million - $18.8 Million
88,600 Added 354.4%
113,600 $21.6 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $4.64 Million - $6.03 Million
-25,000 Reduced 50.0%
25,000 $5.94 Million
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $46.8 Million - $78.3 Million
-337,500 Reduced 87.1%
50,000 $10 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $43.1 Million - $60.5 Million
357,500 Added 1191.67%
387,500 $56.5 Million
Q1 2022

May 13, 2022

SELL
$127.18 - $173.91 $10.4 Million - $14.2 Million
-81,500 Reduced 73.09%
30,000 $4.9 Million
Q4 2021

Feb 11, 2022

BUY
$159.56 - $209.29 $13 Million - $17.1 Million
81,500 Added 271.67%
111,500 $18.9 Million
Q3 2021

Nov 12, 2021

SELL
$169.75 - $207.73 $19 Million - $23.3 Million
-112,100 Reduced 78.89%
30,000 $5.66 Million
Q2 2021

Aug 16, 2021

BUY
$128.63 - $176.89 $11.8 Million - $16.3 Million
92,100 Added 184.2%
142,100 $24.1 Million
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $23.1 Million - $32 Million
-182,000 Reduced 78.45%
50,000 $7.06 Million
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $26.1 Million - $31.2 Million
212,000 Added 1060.0%
232,000 $30.2 Million
Q3 2020

Nov 16, 2020

BUY
$121.19 - $165.49 $2.42 Million - $3.31 Million
20,000 New
20,000 $2.91 Million
Q3 2019

Nov 14, 2019

SELL
$70.9 - $87.82 $2.58 Million - $3.2 Million
-36,400 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$65.86 - $92.79 $2.4 Million - $3.38 Million
36,400 New
36,400 $2.64 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $31.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.